Bone Disorders

FDA Fast Track Designation Granted for Investigational Osteoarthritis Treatment

November 28, 2018

The FDA has granted Fast Track designation for GLPG1972/S201086 for the treatment of patients with osteoarthritis.

Risks of Trazodone Similar to Those of Atypical Antipsychotics

November 27, 2018

The researchers found that use of trazodone correlated with similar rates of falls or major osteoporotic fractures compared with use of atypical antipsychotics.

Bone Erosions More Frequent With Old Age at Onset of Early RA

November 26, 2018

Bone erosions more frequent in those older at early RA onset even if they had clinical remission

CDC: Increases in Yoga, Meditation for Children in 2012-2017

November 09, 2018

The researchers found that from 2012 to 2017, there was an increase in the use of yoga (from 3.1 to 8.4%) and meditation (from 0.6 to 5.4%) during the previous 12 months. In 2017, girls were more likely than boys to have used yoga in the previous 12 months.

Differences in Ankylosing Spondylitis Outcomes Vary by Gender

October 26, 2018

Clinical improvements during treatment with TNF-α inhibitors was comparable between men and women with ankylosing spondylitis.

RAAS Inhibitors and Fracture Risk, Osteoporosis in Postmenopausal Women

October 23, 2018

RAAS inhibitors do not have a deleterious effect on skeletal health in postmenopausal women.

Walking Each Day May Cut Risk for TKA Over 5 Years

October 23, 2018

Researchers assessed the effect of replacing time not walking with walking at very-light, light, or moderate-to-vigorous intensities on the risk for TKA over 5 years.

Zoledronate Lowers Fracture Risk in Women With Osteopenia

October 12, 2018

The researchers found that a fragility fracture occurred in 190 women in the placebo group and 122 women in the zoledronate group (hazard ratio [HR] with zoledronate, 0.63).

Proton Pump Inhibitor Use Tied to Hip Fracture in Dialysis Patients

September 28, 2018

The researchers found that a larger proportion of cases than controls had prior PPI use (70 vs 63%) or histamine-2 receptor antagonist use (25 vs 23%).

Inflammatory Back, Neuropathic Pain May Affect Axial Spondyloarthritis Outcomes

September 07, 2018

Patients with axial spondyloarthritis who have inflammatory back pain or neuropathic pain may have higher pain intensity, pain interference, disease activity, and greater functional limitation compared with individuals with axial spondyloarthritis but without either comorbidity.

PT Better After Hip Surgery Than Opioids in Younger Adults

August 29, 2018

For patients receiving both treatments, the group receiving opioids first had mean hip-related downstream costs that were significantly higher than the group receiving physical therapy first ($18,806 versus $16,955).

Lower Post-Op Mortality With Hip Fx Surgery on Day of Admission

August 24, 2018

Cumulative 30-day in-hospital mortality was 4.9 and 6.9% among patients who were surgically treated on admission day and those who had surgery done after day 3.

Sedation Level Does Not Impact Delirium Risk After Hip Fx Repair

August 13, 2018

The researchers found that the overall incident delirium risk was 36.5%; 39 vs 34%, respectively, in the heavier and lighter sedation groups (P=.46).

Drop in Osteoporosis Treatment Initiation After Hip Fracture

July 27, 2018

The hospital preference instrumental variable had a stronger association with treatment than the other 3 instrumental variables (specialist access, calendar year, and geographic variation) during the effectiveness analyses.

Empagliflozin Does Not Up Risk of Bone Fractures

July 20, 2018

The researchers found that in the pooled analysis, bone fracture AEs were reported in 119 of 4221 patients (2.8%) randomized to empagliflozin 10mg, 105 of 4,196 patients (2.5%) randomized to empagliflozin 25mg, and 123 of 4203 patients (2.9%) randomized to the placebo group.

New Romosozumab BLA Includes Data from Additional Osteoporosis Trials

By July 13, 2018

Evenity is a bone-forming monoclonal antibody designed to inhibit the activity of sclerostin, which allows the drug to rapidly increase bone formation and reduce bone resorption simultaneously.

USPSTF Issues Recommendation on Screening for Osteoporosis

June 28, 2018

Based on these findings, the USPSTF recommends screening for women aged 65 years and older and in younger women who have been through menopause and are at increased risk.

Treatment of Hidradenitis Suppurativa with SAPHO Syndrome: A Case Review

By June 21, 2018

The male patient presented in 2009 with a "3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions."

Binge Drinking Tied to Poorer Bone Health in Young Females

June 15, 2018

The researchers found that frequent HED was associated with decreased vertebral bone mineral density (BMD), even when controlling for variables most commonly associated with bone health such as lean body mass, physical activity, age at menarche, smoking, and oral contraception use.

Many AKI Reports in FAERS Linked to Drugs Not Recognized as Nephrotoxic

By June 12, 2018

According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.

FDA Approves AI Algorithm That Helps Detect Wrist Fractures

By May 25, 2018

OsteoDetect is a computer-aided detection and diagnostic software that uses an algorithm to analyze 2-D wrist radiographs for signs of distal radius fracture.

Prolia Approved for Glucocorticoid-Induced Osteoporosis

By May 22, 2018

The efficacy and safety of Prolia in the treatment of patients with glucocorticoid-induced osteoporosis was assessed in the 12-month primary analysis of a 2-year, randomized, multicenter, double-blind, parallel-group, active-controlled study (N=795).

IV Tramadol Significantly Reduces Post-Op Pain in Phase 3 Study

By May 21, 2018

In this multicenter, double-blind, placebo-controlled trial, patients (N=409) were randomized 1:1:1 to a postoperative regimen of IV tramadol 50mg, IV tramadol 25mg, or placebo administered over 15 minutes at hours 0, 2, 4, and once every 4 hours thereafter (up to 13 doses).

Corticosteroid-Related Adverse Events Examined Based on Dose, Duration

By May 14, 2018

Using a privately-insured administrative database, researchers examined a total of 78,704 patients with autoimmune or inflammatory disease diagnoses between 2006 and 2015.

Anxiety Levels Tied to Bone Mineral Density Post-Menopause

May 14, 2018

There was a significant correlation for anxiety levels with age, menopausal age, years since menopause, and depressive symptoms; multiple regression analysis predicted reduced BMD in the lumbar spine.

Adverse Effect of Osteoporosis Drug May Help Treat Hair Loss

By May 11, 2018

Researchers found that a non-immunosuppressant drug originally designed to treat osteoporosis (WAY-316606) targeted the same mechanism by antagonizing SFRP1, and after treating hair follicles with WAY-316606 for 6 days, the authors found enhanced human hair growth.

Fx Risk Should Be Monitored in Bisphosphonate Drug Holiday

May 11, 2018

The researchers found that 15.4% of the patients developed a fracture during follow-up. Yearly fracture incidence varied from 3.7 to 9.9%, peaking during years four and five at 9.9 and 9.8%, respectively.

Vertebroplasty Does Not Up Pain Relief in Osteoporotic Fracture

May 10, 2018

"Percutaneous vertebroplasty did not result in statistically significantly greater pain relief than a sham procedure during 12 months' follow-up among patients with acute osteoporotic vertebral compression fractures," the authors write.

First FDA-Approved Treatment for X-Linked Hypophosphatemia Launched

By April 30, 2018

Crysvita, a recombinant fully human monoclonal IgG1 antibody, works by blocking fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses vitamin D production by the kidney.

Less Pain Post TKA With Addition of Peripheral Nerve Blocks

April 19, 2018

The researchers found that intervention patients reported lower numeric rating scale pain scores on ambulation than the control group on postoperative day (POD) one (1.7 versus 5.0; P <.001).